

## Communication

## Remote Oxidation of Aliphatic C—H Bonds in Nitrogen Containing Molecules

Jennifer M. Howell, Kaibo Feng, Joseph R. Clark, Louis J. Trzepkowski, and M. Christina White J. Am. Chem. Soc., Just Accepted Manuscript • DOI: 10.1021/jacs.5b10299 • Publication Date (Web): 04 Nov 2015 Downloaded from http://pubs.acs.org on November 5, 2015

## **Just Accepted**

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a free service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are accessible to all readers and citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.



Journal of the American Chemical Society is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036 Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

# Remote Oxidation of Aliphatic C—H Bonds in Nitrogen Containing Molecules

Jennifer M. Howell<sup>‡</sup>, Kaibo Feng<sup>‡</sup>, Joseph R. Clark, Louis J. Trzepkowski and M. Christina White\*

Roger Adams Laboratory, Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois, 61801, United States

Supporting Information Placeholder

**ABSTRACT:** Nitrogen heterocycles are ubiquitous in natural products and pharmaceuticals. Herein, we disclose a nitrogen complexation strategy that employs a strong Brønsted acid (HBF<sub>4</sub>) or an azaphilic Lewis acid (BF<sub>3</sub>) to enable remote, non-directed  $C(sp^3)$ —H oxidations of tertiary (3°), secondary (2°), and primary (1°) amine- and pyridine-containing molecules with tunable iron catalysts. Imides resist oxidation and promote remote functionalization.

The development of reactions that selectively oxidize inert  $C(sp^3)$ —H bonds while tolerating more electron rich nitrogen functionality is a significant, unsolved problem given that nitrogen is ubiquitous in natural products and medicinal agents.<sup>1</sup> Among the challenges for developing such reactions are catalyst deactivation via nitrogen binding and direct oxidation of nitrogen to furnish *N*-oxides. Common electronic deactivation strategies for 2° and 1° amines (e.g. acylation) do not disable hyperconjugative activation leading to functionalization  $\alpha$  to the nitrogen (Figure 1).<sup>2</sup> Directing group strategies facilitate oxidation of  $C(sp^3)$ —H bonds that are spatially and geometrically accessible from the directing functional group.<sup>3</sup> Remote oxidation of  $C(sp^3)$ —H bonds in nitrogen-containing molecules is not currently possible with ligated transition metal catalysis.

Site-selective and -divergent oxidation of tertiary  $(3^{\circ})$  and secondary  $(2^{\circ})$  C—H bonds has been demonstrated with small molecule catalysts, Fe(PDP) **1** and Fe(CF<sub>3</sub>PDP) **2**, respectively.<sup>4</sup> Discrimination of C—H bonds can be accomplished via catalyst/substrate electronic, steric and stereoelectronic interactions. Inductive effects within a substrate



Figure 1. Heterocycle Functionalization

Table 1. Reaction Optimization <sup>a,b</sup>					
Me			i. Ad ii. Fe( oxio	ditive PDP) 1° dation	Me Me
[	Het; piperic N pyridir R <sub>1</sub> R <sub>2</sub>	line 3a-e ne 4a-b	Met	hod A <sup>d</sup>	piperidine <b>5a-e</b> pyridine <b>6a-b</b>
Entry	Heterocycle	R <sub>1</sub>	$R_2$	Additive (equiv)	Yield (%) (rsm) <sup>e</sup>
1	3a	Me	-	BF <sub>3</sub> •OEt <sub>2</sub> (1.1)	46 (28)
2	4a	-	-	BF <sub>3</sub> •OEt <sub>2</sub> (1.1)	27 (67)
3	3a	Me	-	HBF <sub>4</sub> •OEt <sub>2</sub> (1.1)	56 (29)
4	3a	Me	-	F <sub>3</sub> CCO <sub>2</sub> H (1.1)	5 (74)
5 <sup>f</sup>	3a	Me	-	H <sub>2</sub> SO <sub>4</sub> (1.1)	0 (76)
6 <sup>g</sup>	3a	Me	-	HBF <sub>4</sub> •H <sub>2</sub> O (1.1)	43 (40)
7	4a	-	-	HBF <sub>4</sub> •OEt <sub>2</sub> (1.1)	57 (23)
8 <sup>a</sup>	4b	0	-	-	0 (65)
9 <sup>a</sup>	3b	Boc	-	-	n.d. (37)
10 <sup>a</sup>	3c	TFA	-	-	n.d. (11)
11	3d	Н	-	HBF <sub>4</sub> •OEt <sub>2</sub> (1.1)	40 (26)
12 <sup>a,h</sup>	3e	н	$BF_3$	-	44 (22)
13 <sup>a</sup>	$\bigcap$		Fe(F	PDP) 1°	70 (8)
	o∽n~	0	oxic	dation O <sup>™</sup> N <sup>↑</sup>	<sup>©</sup> 0
Me					
glutarimide 3f <sup>I</sup> `H glutarimide 5f <mark>V`OH</mark> Me					Me
$\begin{bmatrix} & \text{Me} & 1. \text{ MJ} \text{ 4 OL} 12 \\ & \text{ii. Fe}(CF_3PDP) 2^c \end{bmatrix} \xrightarrow{\text{p}} \overset{\text{p}}{\gamma} \overset{\text{s}}{\gamma} \text{ Me}$					
(Het) piperidine 3g -				hod B <sup>i</sup>	piperidine <b>5g</b> pyridine <b>6c-d</b>
	Ŕ			Ŕ	
Entry	Heterocycle	R		Yield (%) (rsm) <sup>e</sup>	Selectivity <sup>j</sup>
14	3g	Me		57 (4)	1:1 δ/mixture
15	4c	-		53 (10)	2.6:1 δ/γ

<sup>a</sup>Iterative addition (3x): 5 mol% **1**, AcOH (0.5 equiv), H<sub>2</sub>O<sub>2</sub> (1.2 equiv), MeCN (ref 4a). <sup>b</sup>Slow addition: 25 mol% **2**, AcOH (5.0 equiv), H<sub>2</sub>O<sub>2</sub> (9.0 equiv), MeCN, syringe pump 6 mL/min (ref 4b,c). <sup>c</sup>Catalyst enantiomers used interchangeably. <sup>d</sup>Method A: (i) Additive (1.1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, concd in vacuo, (ii) Iterative addition, (iii) 1M NaOH. <sup>e</sup>Isolated yields, % recovered starting material (rsm). <sup>h</sup>No product observed with H<sub>2</sub>SO<sub>4</sub> (0.55 equiv). <sup>g</sup>In situ addition of HBF<sub>4</sub> (1.1 equiv). <sup>h</sup>2<sup>o</sup> Piperidine-BF<sub>3</sub> complex **3e** isolated and purifed. Product **5e** isolated/purified as 2<sup>o</sup> piperidine-BF<sub>3</sub> complex. <sup>t</sup>Method B: (i) HBF<sub>4</sub>•OEt<sub>2</sub> (1.1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, concd in vacuo, (ii) Slow addition, (iii) 1M NaOH. Based on isolation.

strongly influence site-selectivity, as highly electrophilic metal oxidants (e.g. Fe=O) disfavor oxidation of electrondeficient  $C(sp^3)$ —H bonds. Functionalities with positive charges, such as ammonium cations, or strongly polarized dative bonds, such as amine-borane adducts, exert a strong inductive effect on adjacent C—H bonds.<sup>5</sup> We hypothesized that Lewis/Brønsted acid complexation of nitrogen would afford nitrogen tolerance and remote site-selectivity in ironcatalyzed  $C(sp^3)$ —H oxidations. Herein, we describe strategies that enable remote, non-directed aliphatic C—H oxidation in substrates containing prevalent nitrogen functional groups: amines (3°, 2°, 1°) and pyridines. Imides tolerate oxidative conditions without complexation and promote remote  $C(sp^3)$ —H oxidation.

We evaluated two strategies to effect nitrogen tolerance/remote oxidation: azaphilic, oxidatively stable Lewis acid complexation with boron trifluoride (BF<sub>3</sub>) and irreversible protonation with tetrafluoroboric acid (HBF<sub>4</sub>), a strong Brønsted acid with a weakly coordinating counterion. Whereas some precedent exists with these strategies for C-H oxidations,<sup>6</sup> olefin oxidations<sup>7a-b</sup> and metathesis,<sup>7c</sup> no examples of remote aliphatic C—H oxidations under ligated transition metal catalysis are known. In metal complexes having basic, dative ligands (e.g. PDP), competitive complexation with acid may lead to catalyst deactivation. Exploration of BF<sub>3</sub> complexation with both 3° piperidine **3a** and pyridine 4a provided encouraging yields of remotely oxidized products (Table 1, entries 1, 2). HBF<sub>4</sub> protonation afforded remote oxidation products with improved yields for both **3a** and **4a** (entries 3, 7). The same protocol with trifluoroacetic acid or sulfuric acid,<sup>6c</sup> which generate more coordinating counterions, resulted in decreased yield (entry 4, 5). An in situ HBF4 protocol resulted in diminished yield of 5a, suggesting excess acid is not beneficial (entry 6). Oxidation of pyridine *N*-oxide **4b** was unproductive (entry 8).<sup>6a</sup>

Oxidation of acyl-protected piperidines (3b-c, entries 9, 10) resulted in over-oxidized products, likely via *N*dealkylation pathways. Both HBF<sub>4</sub> protonation and BF<sub>3</sub> complexation are effective with 2° piperidine **3d** (entries 11, 12). The BF<sub>3</sub> complexation strategy is preferable for 2° and 1° amines due to facile purification of oxidized amine-BF<sub>3</sub> complexes. Additionally, these complexes can be stored without precaution to exclude atmosphere.<sup>8</sup> Despite indiscriminate oxidation of carbamates and amides, we found that imides attenuate nitrogen basicity and enable remote oxidation (entry 13).



Remote methylene oxidation of piperidine **3g** and pyridine **4c** with  $Fe(CF_3PDP)^{4c}$  afforded good overall yields but with significantly diminished site-selectivities (Table 1, entries 14, 15). In contrast, Fe(PDP) hydroxylation of remote 3° C—H bonds proceeds with high site-selectivity; no benzylic or methylene oxidation products were detected. HBF<sub>4</sub> protonation/oxidation of a linear substrate with competing 3° sites proceeded with excellent selectivity (>20:1 distal/proximal), favoring the site distal from the protonated amine (eq 1). Electron-withdrawing groups (e.g. Br, F, OAc) previously evaluated did not afford such strong inductive deactivation of proximal sites (9:1, 6:1, 5:1 distal/proximal,





Psolated yield is average of two runs, % rsm in parentheses. <sup>b</sup>Catalyst enantiomers used interchangeably. <sup>M</sup>Method A with HBF<sub>4</sub>•Et<sub>2</sub>O (1.1 equiv). <sup>d</sup>Method B. <sup>e</sup>Starting material recycled 1x. <sup>M</sup>Method B with 1. <sup>M</sup>Method A with BF<sub>3</sub>•Et<sub>2</sub>O (1.1 equiv) concd and purified prior to use. Isolated as BF<sub>3</sub>-complex, no NaOH workup. <sup>M</sup>Method A with BF<sub>3</sub>•Et<sub>2</sub>O (1.1 equiv). <sup>M</sup>Method B with BF<sub>3</sub>•Et<sub>2</sub>O (1.1 equiv) concd and purified prior to use. Isolated as BF<sub>3</sub>-complex, no NaOH workup.





respectively).<sup>4a</sup> Collectively, these data suggest that Brønsted/Lewis acid complexation renders basic nitrogen a strong inductive withdrawing moiety, enabling remote C— H oxidations often with high site-selectivities.

Piperidines substituted at N, C4, and C2 are the most prevalent nitrogen heterocycles in drugs.<sup>1a</sup> Employing HBF<sub>4</sub> protonation, Fe(PDP)-catalyzed tertiary oxidations of Nmethyl or N-alkyl substituted piperidines proceeded uniformly in high yields and with excellent site-selectivities to afford 3° hydroxylated products (Table 2). Notably, piperidine 9a with C2-alkyl substitution was hydroxylated in 52% yield (10a), showcasing the effectiveness of HBF<sub>4</sub> protonation in sterically hindered environments. Piperidines with a variety of functional groups (esters, nitriles, electron deficient aromatics) perform well under conditions where competitive hydrolysis or oxidation may occur (10b-f). The 4phenylpiperidine motif in 10d-e represents a pharmacophore found in opioids such as ketobemidone and haloperidol.<sup>9</sup> Improved site-selectivities for Fe(CF<sub>3</sub>PDP)-catalyzed remote methylene oxidations were observed in substrates having more electronic differentiating elements (10e and **10f**, 40% and 50%, respectively).

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

Analogous 2° piperidine-BF<sub>3</sub> complexes worked with equal facility for remote tertiary and secondary oxidations (Table 2). Underscoring the variance in electronics between 3° and 2° C—H bonds, oxidation of 9j delivered 3° alcohol 10j in 65% yield, whereas methylene oxidation of 9k gave trace product. The BF<sub>3</sub> complexation strategy is preferred for oxidation of sterically unencumbered 2° and 1° amines (10n), where challenges in product isolation with HBF<sub>4</sub> protonation lead to diminished isolated yields (10l vs 10m). Protonation with HBF4 is advantageous in cases where steric hindrance at nitrogen retards effective BF<sub>3</sub> coordination (10i 56% and 43% yield, respectively). Hydroxylated amine-BF<sub>3</sub> complexes are readily converted to the free amine via basemediated hydrolysis or exposure to a nucleophilic fluoride source (Scheme 1). The latter protocol is advantageous for substrates containing hydrolytically unstable functional groups, such as 10g.

Pyridines are the most prevalent heteroaromatic in FDA approved pharmaceuticals.<sup>1a</sup> Fe(PDP)-catalyzed remote hydroxylation of 3° sites in 2-alkylpyridines proceeded smoothly using HBF<sub>4</sub> protonation for both mono- and disubstituted substrates (13a 59%, 13b 61%, Table 3). In these sterically encumbered substrates, complexation with BF<sub>3</sub> affords diminished yields (32% and 34%, respectively). Long-chain 3-alkylpyridines, prevalent in natural products,<sup>10</sup> are efficiently oxidized (13c 50%). Remote oxidation proceeds in good yields with electron rich pyridines (**6a**, **13d**) whereas yield and mass balance are lower with an electron deficient substrate (13e 34% yield, 29% recovered starting material (rsm)). Pyridines having less electronically favored and exposed 3° sites afford modest site-selectivity (13f 52%, 2.7:1). The one carbon shortened analog of 4-pentylpyridine (4c, Table 1) underwent methylene oxidation with improved site-selectivity (>20:1) but in diminished yield (13g 32% yield). In cyclohexanes<sup>4b</sup> having bulky, inductive withdrawing substituents, stereoelectronic preference for oxidation at C3 overrides electronic preference for oxidation at C4 (**13h** 1.6:1 C3/C4 adjusted for number of hydrogens).

Imides are abundant in biologically active molecules and serve as synthetic precursors to amines.<sup>11</sup> Succinimide 14a and glutarimide 14b were oxidized in excellent yield, without requirement for Brønsted/Lewis acid complexation, to afford the corresponding alcohols (Table 4). Cyclopropyl modified succinimides are tolerated in this C-H oxidation reaction (15c-d). Spirocyclic glutarimide 14f, a substructure in anxiolytic agent buspirone,<sup>12</sup> underwent site-selective methylene oxidation in good yield (57%). Analogous to reactivity in enzymatic oxidations,<sup>1b</sup> we have observed Fe(PDP) to effect both oxidative N-dealkylation of amines and oxidation of electron neutral or rich aromatics. No Ndemethylation was observed with imide 14e (57%) and both 4-nitrophthalimide 14g and unsubstituted phthalimide 14h were oxidized in useful yields (15g 58%; 15h 46%).<sup>13</sup> Underscoring the medicinal relevance of this reaction, oxidation of thalidomide analog 14i afforded 15i in good yield

Table 3. Pyridines<sup>a</sup>



<sup>a</sup>Isolated yield is average of two runs, % rsm in parentheses. <sup>b</sup>Catalyst enantiomers used interchangeably. <sup>c</sup>Method A with HBF<sub>4</sub>•Et<sub>2</sub>O (1.1 equiv). <sup>d</sup>Method B with BF<sub>3</sub>•OEt<sub>2</sub> (1.1 equiv), catalyst 1 and 20% NaOH workup. <sup>e</sup>(+)-13f Refers to pure alcohol. <sup>f</sup>Starting material recycled 1x. <sup>c</sup>Based on isolation. <sup>*t*</sup>Method B. <sup>i</sup>1.6:1 C3/C4 adjusted for number of hydrogens.



<sup>a</sup>Isolated yield is average of two runs, % rsm in parentheses. <sup>b</sup>Iterative addition. <sup>c</sup>Catalyst enantiomers used interchangeably. <sup>d</sup>Starting material recycled 1x.

(54%). Imides are oxidatively stable and inductively deactivating motifs that promote remote oxidations.

We evaluated efficacy of the aforementioned nitrogen protection strategies paired with Fe(PDP) or Fe(CF<sub>3</sub>PDP) oxidation in late-stage diversification of medicinally important complex molecules. Dextromethorphan, an antitussive drug of the morphinan class, contains a basic *N*-methyl piperidine moiety, an aromatic ring and a benzylic site, all highly prone to oxidation (Scheme 2A). We hypothesized that benzylic deactivation would result from the proximally fused tertiary piperidine, which as its ammonium BF<sub>4</sub> salt would be rendered a strong inductive withdrawing group. Exposure of **16** to HBF<sub>4</sub> protonation/Fe((*S*,*S*)-CF<sub>3</sub>PDP) oxidation afforded remote, non-benzylic oxidation products, ketone **17** and alcohol **18** in 45% yield with preference for the least sterically hindered methylene site (2.5:1 ketone/alcohol).

Abiraterone acetate, having a C17-(3-pyridyl) motif, is a steroidal antiandrogen used in the treatment of prostate cancer. Despite a strong preference for oxidation at 3° benzylic sites (BDE~83 kcal/mol),<sup>14</sup> exposure of **19** to HBF<sub>4</sub> protonation/Fe((R,R)-CF<sub>3</sub>PDP) oxidation resulted in a site-selective remote oxidation at C6 (BDE~98 kcal/mol) of the steroid core in 42% yield (6:1 alcohol/ketone) (Scheme 2B).

Scheme 2. Late-Stage Functionalization of Nitrogen Containing Molecules<sup>a</sup>



<sup>a</sup>Isolated yield is average of two runs. <sup>b</sup>Substrates containing chirality demonstrated matched/mis-matched reactivity with catalyst enantiomers. <sup>c</sup>(i) HBF<sub>4</sub>•Et<sub>2</sub>O (1.1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, concd in vacuo, (ii) Slow addition with **2**, (iii) 1M NaOH. <sup>a</sup>Based on isolation. <sup>e</sup>(+)-**20** Refers to pure alcohol. <sup>f</sup>(i) HBF<sub>4</sub>•Et<sub>2</sub>O (1.1 equiv), CH<sub>2</sub>Cl<sub>2</sub>, concd in vacuo, (ii) Iterative addition with **2**, (iii) NaHCO<sub>3</sub>. <sup>g</sup>Starting material recycled 2x. <sup>h</sup>Iterative addition with **1**.

These represent the first examples of transition metal catalyzed remote, aliphatic C—H oxidations on a morphinan and nitrogen-containing steroid skeletons.

Cycloheximide, a readily available natural product with broad antimicrobial activity but high toxicity is currently used as a protein synthesis inhibitor. The C4 hydroxylated analogue, streptovitacin A **22**, has shown diminished toxicity and has been obtained via an eight step de novo synthesis proceeding in 7% overall yield.<sup>15</sup> The direct oxidation of cycloheximide derivative **21** with Fe((S,S)-PDP) affords streptovitacin A derivative **23** in excellent yield (50%) (Scheme 2C), underscoring the power of remote late stage C—H oxidation to streamline synthesis.

We have demonstrated remote Fe(PDP)-catalyzed oxidation in a range of nitrogen heterocycles by employing Brønsted/Lewis acid complexation strategies. We envision this will be a highly enabling methodology for the generation of medicinal agents via late-stage oxidation and for the evaluation of their metabolites.

#### ASSOCIATED CONTENT

**Supporting Information**. This material is available free of charge via the Internet at http://pubs.acs.org.

#### AUTHOR INFORMATION

Corresponding Author

mcwhite7@illinois.edu

Author Contributions

<sup>‡</sup>These authors contributed equally.

Funding Sources

Financial support was provided by the NIH/NIGMS (GM 112492).

#### ACKNOWLEDGMENT

We thank G. Snapper for initial investigations, J. Griffin, J. Zhao and T. Osberger for spectra inspection, C. Delaney for checking procedures, Dr. L. Zhu for assistance with NMR data analysis, Dr. J. Bertke and Dr. D. Gray for crystallographic data and analysis. We thank Zoetis for an unrestricted grant to explore C—H oxidations in pharmaceuticals.

#### REFERENCES

(1) (a) Vitaku, E.; Smith, D. T.; Njardarson, J. T. *J. Med. Chem.* **2014**, *57*, 10257. (b) White, M. C. *Science* **2012**, *335*, 807. (c) Nam, W.; Lee, Y.-M.; Fukuzumi, S. *Acc. Chem. Res.* **2014**, *47*, 1146.

(2) (a) Campos, K. R. Chem. Soc. Rev. 2007, 36, 1069. (b) Catino, A. J.; Nichols, J. M.; Nettles, B. J.; Doyle, M. P. J. Am. Chem. Soc. 2006, 128, 5648. (c) Condie, A. G.; González-Gómez, J. C.; Stephenson, C. R. J. J. Am. Chem. Soc. 2010, 132, 1464. (d) Hari, D. P.; König, B. Org. Lett. 2011, 13, 3852. (e) Noble, A.; MacMillan, D. W. C. J. Am. Chem. Soc. 2014, 136, 11602. (f) He, J.; Hamann, L. G.; Davies, H. M. L.; Beckwith, R. E. J. Nat. Commun. 2015, 6, 5943.

(3) (a) McNally, A.; Haffemayer, B.; Collins, B. S. L.; Gaunt, M. J. *Nature* **2014**, *510*, 129. (b) Chan, K. S. L.; Wasa, M.; Chu, L.; Laforteza, B. N.; Miura, M.; Yu, J.-Q. *Nat. Chem.* **2014**, *6*, 146.

(4) (a) Chen, M. S.; White, M. C. *Science* **2007**, *318*, 783. (b) Chen, M. S.; White, M. C. *Science* **2010**, *327*, 566. (c) Gormisky, P. E.; White, M. C. *J. Am. Chem. Soc.* **2013**, *135*, 14052.

(5) (a) Anslyn, E. V.; Dougherty, D. A. *Modern Physical Organic Chemistry*; University Science Books: California, 2006; pp 15-16. (b) Staubitz, A.; Robertson, A. P. M.; Sloan, M. E.; Manners, I. *Chem. Rev.* **2010**, *110*, 4023.

(6) Pyridines in Pd(II)/sulfoxide allylic C—H oxidation: (a) Malik, H. A.; Taylor, B. L. H.; Kerrigan, J. R.; Grob, J. E.; Houk, K. N.; Du Bois, J.; Hamann, L. G.; Patterson, A. W. *Chem. Sci.* **2014**, *5*, 2352. Aliphatic amines with methyl(trifluoromethyl) dioxirane (TFDO): (b) Asensio, G.; González-Núñez, M. E.; Bernardini, C. B.; Mello, R.; Adam, W. *J. Am. Chem. Soc.* **1993**, *115*, 7250. Shilov oxidation of aliphatic amines (5 equiv): (c) Lee, M.; Sanford, M. S. *J. Am. Chem. Soc.* **2015**, *137*, 12796.

(7) (a) Ferrer, M.; Sánchez-Baeza F.; Messeguer, A.; Diez, A.; Rubiralta, M. *J. Chem. Soc., Chem. Commun.* **1995**, 293. (b) Brennan, M. B.; Claridge, T. D. W.; Compton, R. G.; Davies, S. G.; Fletcher, A. M.; Henstridge, M. C.; Hewings, D. S.; Kurosawa, W.; Lee, J. A.; Roberts, P. M.; Schoonen, A. K.; Thomson, J. E. *J. Org. Chem.* **2012**, *77*, 7241. (c) Woodward, C. P.; Spiccia, N. D.; Jackson, W. R.; Robinson, A. J. Chem. Commun. **2011**, *47*, 779.

(8) Hampe, E. M.; Rudkevich, D. M. Tetrahedron 2003, 59, 9619.

(9) Zimmerman, D. M.; Nickander, R.; Horng, J. S.; Wong, D. T. *Nature* **1978**, *275*, 332.

(10) O'Hagan, D. Nat. Prod. Rep. **1997**, 14, 637.

(11) Gören, M. Z.; Onat, F. CNS Drug Rev. 2007, 13, 224.

(12) Wu, Y.-H.; Rayburn, J. W.; Allen, L. E.; Ferguson, H. C.; Kissel, J. W. J. Med. Chem. **1972**, *15*, 477.

(13) Schmidt, V. A.; Quinn, R. K.; Brusoe, A. T.; Alexanian, E. J. J. Am. Chem. Soc. 2014, 136, 14389.

(14) Luo, Y.-R.; Cheng, J.-P. in *CRC Handbook of Chemistry & Physics* 94<sup>th</sup> Ed. (ed. Haynes, W. M.) pp. 9-65 (CRC, 2013).

(15) Kondo, H.; Oritani, T.; Yamashita, K. Agric. Biol. Chem. **1990**, *54*, 1531.

## Journal of the American Chemical Society

